Spyre Therapeutics (NASDAQ: SYRE) granted equity inducement awards to six non-executive employees under its 2018 Equity Inducement Plan.
The awards include stock options for 58,843 shares at an exercise price of $88.89 with a 10-year term, plus 2,134 RSUs, all subject to multi-year vesting and continued service.
Loading...
Loading translation...
Positive
Equity inducement of 58,843 options and 2,134 RSUs to attract talent
10-year option term at $88.89 aligns employees with long-term share performance
Structured multi-year vesting supports employee retention and continuity
Negative
New equity awards may modestly dilute existing shareholders over time
Additional stock-based compensation will add to future compensation expense
News Market Reaction – SYRE
+2.44%
+2.44%Session close to close
In the Jul 6 session, SYRE gained 2.44%, reflecting a moderate positive market reaction.
Spyre’s latest move grants 58,843 option shares and 2,134 RSUs to six new employees at an $88.89 str...
Analysis
Spyre’s latest move grants 58,843 option shares and 2,134 RSUs to six new employees at an $88.89 strike. Against an effective ATM shelf and elevated short interest, investors may monitor how equity compensation and any future issuance interact with insider selling trends.
Key Figures
Stock options granted:58,843 sharesRSUs granted:2,134 RSUsEmployees receiving awards:6 employees+5 more
8 metrics
Stock options granted58,843 sharesAggregate options to six non-executive employees under 2018 Plan
RSUs granted2,134 RSUsEquity inducement awards to six non-executive employees
Q1 2026 results with strong cash position and multiple Phase 2 readouts planned.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent substantive R&D and earnings updates have tended to see positive next-day moves, while logistical or administrative items show more mixed reactions.
"and 2,134 restricted stock units (“RSUs”) to six non-executive employees"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
equity inducement awardsfinancial
"as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
nasdaq listing rule 5635(c)(4)regulatory
"with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"a 10-year term and an exercise price equal to $88.89, the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 58,843 shares of common stock of Spyre and 2,134 restricted stock units (“RSUs”) to six non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on July 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted with a 10-year term and an exercise price equal to $88.89, the closing price per share of Spyre's common stock as reported by Nasdaq on July 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The RSUs granted to the employees shall vest as to one-fourth (1/4th) of the shares subject to the respective RSUs on each anniversary of the next February 15, May 15, August 15, or November 15 occurring on or after the employee’s start date, subject to continuous service with Spyre through the applicable vesting dates. The stock options and RSUs are subject to the terms of the 2018 Plan.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please visit http://spyre.com.
For Investors: Eric McIntyre SVP of Finance and Investor Relations Spyre Therapeutics Eric.mcintyre@spyre.com
FAQ
What inducement equity awards did Spyre Therapeutics (NASDAQ: SYRE) grant in July 2026?
Spyre Therapeutics granted stock options for 58,843 shares and 2,134 restricted stock units as inducement awards to six non-executive employees. According to Spyre, these awards were granted under its 2018 Equity Inducement Plan and were material to each employee’s acceptance of employment.
What is the exercise price and term of Spyre Therapeutics (SYRE) inducement stock options?
The inducement stock options have a 10-year term and an exercise price of $88.89 per share. According to Spyre, this price equals the July 1, 2026 Nasdaq closing price of its common stock, aligning option value with the market at grant.
How do Spyre Therapeutics (SYRE) inducement stock options vest for new employees?
Spyre’s inducement stock options vest 25% on the first anniversary of each employee’s start date, with the remaining shares vesting monthly thereafter. According to Spyre, one-forty-eighth of the option shares vests each month, subject to continuous service through the applicable vesting dates.
What is the vesting schedule for Spyre Therapeutics (SYRE) inducement RSUs?
Spyre’s inducement RSUs vest in four equal annual installments tied to quarterly dates. According to Spyre, 25% of each RSU grant vests on each anniversary of the next February 15, May 15, August 15, or November 15 after the employee’s start date, subject to continuous service.
Why did Spyre Therapeutics grant inducement awards under the 2018 Equity Inducement Plan?
Spyre used its 2018 Equity Inducement Plan to grant stock options and RSUs that were material to each employee’s job acceptance. According to Spyre, these awards were approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4) for new hires.
How many employees received Spyre Therapeutics (SYRE) inducement equity grants in July 2026?
Six non-executive employees received inducement equity grants consisting of stock options and RSUs. According to Spyre, the Compensation Committee approved these awards on July 1, 2026 as part of employment offers, using shares available under the 2018 Equity Inducement Plan.
